The presence of  staphylococcal superantigens in nasal swabs and correlation with activity of granulomatosis with polyangiitis (GPA) in own material.

J. Fijolek (Warsaw, Poland), E. Wiatr (Warsaw, Poland), V. Petroniec (Warsaw, Poland), E. Augustynowicz-Kopec (Warsaw, Poland), M. Bednarek (Warsaw, Poland), D. Gawryluk (Warsaw, Poland), M. Martusewicz-Boros (Warsaw, Poland), K. Modrzewska (Warsaw, Poland), E. Radzikowska (Warsaw, Poland), K. Roszkowski-Sliz (Warsaw, Poland)

Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Disease area: Interstitial lung diseases

Congress or journal article abstract

Abstract

Objective: We investigated the association between  a presence of  staphylococcal superantigens (SAg) in nasal swabs  and activity of  disease in granulomatosis with polyangiitis (GPA) patients  taking into account correlation with antineutrophil  cytoplasmic antibodies (ANCA) and antimicrobial treatment.

Methods: In a prospective study of all 150 GPA patients hospitalized in the period 2009-2016 nasal swabs were examinated for presence of  Staphylococcus aureus and SAg. Subsequently,  the association with  disease activity was assessed.  

Results: Of 362 Staphylococcus aureus – positive nasal swab culture a presence at least one SAg in 126 samples (34,8%) from 56 patients (48,7%) was found. We did not find the significant correlation between presence of SAg  and  disease activity (p=0,986),  although when individual  SAg were analyzed separatively, SED and TSST-1 were more frequently present in active disease. Additionaly,  the results of the analysis demonstrated a significant correlation between ANCA and activity of GPA (0R 1.42, p=0,0034)  and a protective effect of  trimethoprim/sulfamethoxazole (T/S) treatment (0R 0.52, p<0,0092).   GPA  limited  to SGS appeared as  an unfavorable  factor  associated with disease activity (0R 1.84, p=0.05). 

Conclusion: The association between  staphylococcal SAg in nasal swabs and activity of GPA is not evident. Multiple mechanisms that may lead to disease activation still need to be investigated.

 

 



Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Fijolek (Warsaw, Poland), E. Wiatr (Warsaw, Poland), V. Petroniec (Warsaw, Poland), E. Augustynowicz-Kopec (Warsaw, Poland), M. Bednarek (Warsaw, Poland), D. Gawryluk (Warsaw, Poland), M. Martusewicz-Boros (Warsaw, Poland), K. Modrzewska (Warsaw, Poland), E. Radzikowska (Warsaw, Poland), K. Roszkowski-Sliz (Warsaw, Poland). The presence of  staphylococcal superantigens in nasal swabs and correlation with activity of granulomatosis with polyangiitis (GPA) in own material.. 3035

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Granulomatosis with polyangiitis (Wegener&s)
Source: Eur Respir Mon 2011; 54: 1-14
Year: 2011


New biomarkers for early diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA)
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017


Lung-limited Granulomatosis with polyangiitis (GPA) managed without immunosuppression
Source: International Congress 2018 – CC5 Pulmonary vasculitis: the great chameleon
Year: 2018


Wegener‘s granulomatosis (WG) limited to the lungs
Source: Eur Respir J 2004; 24: Suppl. 48, 49s
Year: 2004

Frequency of eosinophilic granulomatosis with polyangiitis in Europe by meta-analysis
Source: Virtual Congress 2020 – Prevalence and incidence of chronic lung diseases
Year: 2020


Involvement of the respiratory tract in granulomatosis with polyangiitis - bronchoscopic point of view
Source: International Congress 2019 – Interventional pulmonology: diagnostic techniques and obstructive airway disease
Year: 2019


Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
Source: ERJ Open Res, 6 (4) 00451-2020; 10.1183/23120541.00451-2020
Year: 2020



Physiological characteristics in patients with microscopic polyangitis (MPA) and wegener‘s granulomatosis (WG)
Source: Eur Respir J 2004; 24: Suppl. 48, 327s
Year: 2004

Wegener's granulomatosis (WG) - clinical features and response to treatment in 18 cases
Source: Eur Respir J 2002; 20: Suppl. 38, 64s
Year: 2002

Coexistent granulomatosis with polyangiitis (Wegener‘s) and Crohn disease: A clinicopathologic description of cases
Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases
Year: 2012

Eosinophilic granulomatosis with polyangiitis
Source: Eur Respir Monogr 2019; 86: 188-209
Year: 2019


Eosinophilic granulomatosis with polyangiitis
Source: Eur Respir Monogr 2022; 95: 177-192
Year: 2022


Neutrophil chemotaxis in granulomatosis with polyangiitis (Wegener’s) and idiopathic pulmonary fibrosis
Source: Eur Respir J 2011; 38: 1081-1088
Year: 2011



Biologics for eosinophilic granulomatosis with polyangiitis
Source: Short video statement 2020
Year: 2020

Alveolar haemorrhage syndromes
Source: Eur Respir Mon 2011; 54: 15-31
Year: 2011


Microscopic polyangiitis and granulomatosis with polyangiitis
Source: Eur Respir Monogr 2019; 86: 153-172
Year: 2019


Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)
Source: Eur Respir J 2016; 48: 1429-1441
Year: 2016



Different disease subtypes in allergic eosinophilic granulomatosis with polyangiitis (EGPA)
Source: Annual Congress 2013 –Clinical management of orphan lung diseases
Year: 2013


Aerosolized tobramycin in patients with Wegener's granulomatosis
Source: Eur Respir J 2001; 18: Suppl. 33, 138s
Year: 2001

Wegener granulomatosis : review of 16 cases
Source: Eur Respir J 2002; 20: Suppl. 38, 314s
Year: 2002